Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04373590
Other study ID # 24734
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 27, 2019
Est. completion date August 30, 2020

Study information

Verified date February 2021
Source Temple University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the impact of an antipsychotic medication decision aid and interpersonal and cognitive factors, such as attachment style and motivation, on emerging adults' ability to engage in shared decision making regarding their medications.


Description:

The long-term occupational, social, and economic outcomes associated with psychosis make it an urgent public health problem. Coordinated specialty care (CSC) is now the gold standard for early psychosis, demonstrating positive clinical and functional effects in the short-term, and longer-term reduced hospitalization rates. These services include an array of treatment options, including psychotropic medications, individual psychotherapy, family education, and support, and occupational therapy and supported employment/education. While a shorter period between psychosis onset and receipt of appropriate care is associated with better outcomes, emerging adults often experience significant delays before receiving treatment, and a large percentage disengage from services once they are commenced. Decisional conflict about treatment options (i.e., feeling conflicted about which option to choose) and interpersonal factors such as attachment style and trust in health providers can contribute to decision delay and discontinuance of chosen options. Decision support tools (e.g., decision aids), have been shown to reduce decisional conflict as well as improve service engagement. A requisite step in expanding the array of decision support tools available to emerging adults experiencing early psychosis is to better understand their decision-making ability, capacity, and motivation to engage in decision making and how these relate to their engagement in CSC. It is well recognized that individuals who are being prescribed antipsychotic medications often face decisional conflict about their treatment options. An especially controversial decision is whether individuals should continue taking medication at the same dose or adjust the dose whilst monitoring their symptoms. This dilemma is the result of some uncertainty about the appropriate treatment strategy for long-term management of psychosis. The present project focuses on evaluating the feasibility and effectiveness of the use of a decision aid for making decisions about antipsychotic medication.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date August 30, 2020
Est. primary completion date August 12, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria: - Aged 18 to 25 years - Experiencing early psychosis, defined as psychosis lasting 18 months or less between the time when threshold symptom criteria were reached (as determined by the admitting CSC program assessor) and the date of CSC program enrollment - Planning to attend a medication appointment with a participating CSC psychiatrist - Ability to speak and understand English - Ability to provide informed consent as assessed by research staff using procedures discussed by Carpenter et al. (2000) including a demonstrated understanding and recall of study procedures, rather than passive consent, and allowance of repetition of study procedures until there is understanding and recall. Exclusion Criteria: - Have a legal guardian - Have identified co-occurring dementia, delirium, or intellectual disability that will likely affect their ability to provide informed consent or participate in the data collection procedures.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Decision aid
The chosen intervention is a one-page DA developed by the first author, published and fully described elsewhere (Zisman-Ilani et al., 2017; Zisman et al., 2018) for use during the psychiatric consultation to help patients and clinicians discuss relevant treatment options pertaining to antipsychotics such as medication nonadherence and self-tapering. The DA format is a simple one-page table with rows containing frequently asked questions by patients about their treatment options and the benefits, risks, and implications of differing decisions. The columns display the treatment options available for the treatment decision in question: continuing, adjusting, or discontinuing antipsychotic medications.

Locations

Country Name City State
United States Psychosis Education, Assessment, Care and Empowerment (PEACE) Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Temple University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Zisman-Ilani Y, Shern D, Deegan P, Kreyenbuhl J, Dixon L, Drake R, Torrey W, Mishra M, Gorbenko K, Elwyn G. Continue, adjust, or stop antipsychotic medication: developing and user testing an encounter decision aid for people with first-episode and long-te — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in antipsychotics knowledge Scale to assess change in knowledge about antipsychotic medications over time (9 items) Baseline (Pre-appointment interview ) and post appointment interview ( same 1 day of the appointment )
Primary Decision-making self-efficacy Decision Self-Efficacy (DSE) scale to assess decision self-efficacy (11 items) Post appointment interview (1 day of the appointment )
Primary Decision-making attitudes Decision Attitude Scale (DAS) to assess decision-making attitudes (10 items) Post appointment interview (1 day of the appointment )
Primary Decisional Conflict Decisional Conflict Scale (DCS) to assess level of decisional conflict (15 items) Post appointment interview (1 day of the appointment )
Primary Shared decision making collaboRATE scale to assess level of shared decision making after an appointment (3 items) Post appointment interview (1 day of the appointment )
Primary Change in medication adherence Brief Adherence Rating Scale (BARS) to assess change in medication adherence over time (8 items) Baseline (Pre-appointment interview ) and post appointment interview ( same 1 day of the appointment ), 3 months follow-up , 6 months follow-up .
Primary Change in service use Service Use and Resource Form for Monthly Items (SURF-M) scale to assess change in service use over time (66 items) Baseline (Pre-appointment interview ) and post appointment interview ( same 1 day of the appointment ), 3 months follow-up , 6 months follow-up .
Primary Service engagement Service Engagement Scale (SES) to assess level of service engagement (14 items) Baseline (Pre-appointment interview )
Secondary Apathy Marin Apathy Evaluation Scale to assess apathy (18 items) Baseline (Pre-appointment interview )
Secondary Attachment style Experiences in Close Relationships-Revised (ECR-R) Questionnaire to assess attachment style (36 items) Baseline (Pre-appointment interview )
Secondary Working alliance Working Alliance Inventory (WAI) to assess alliance (36) Baseline (Pre-appointment interview )
Secondary Trust Trust in the Medical Profession Scale to assess level of trust in the clinician (11 items) Baseline (Pre-appointment interview )
Secondary Cognitive functioning Brief Assessment of Cognition in Schizophrenia (BACS) - a battery to assess aspects of cognition such as verbal memory and attention. Baseline (Pre-appointment interview )
Secondary Insight Birchwood Insight Scale to assess insight to the illness (8 items) Baseline (Pre-appointment interview )
Secondary Self-stigma Internalized Stigma of Mental Illness (ISMI) Scale - Brief Version, to assess mental health self-stigma (10 items) Baseline (Pre-appointment interview )
See also
  Status Clinical Trial Phase
Recruiting NCT06032182 - PSYCHE Cognitive Remediation & Social Recovery Study N/A
Active, not recruiting NCT06192602 - Effects of an Acceptance-based Medication Adherence Therapy for Recent-onset Psychosis N/A
Recruiting NCT04411225 - Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis Phase 3
Completed NCT04592042 - Intervention to Improve Coping With Negative Emotions in Patients With Psychosis (Feel-Good-Study) Early Phase 1
Active, not recruiting NCT04166019 - Effect of a Peer-led Self-management Program for Recent-onset Psychosis N/A
Recruiting NCT04317807 - R33: Levetiracetam in Early Psychosis Phase 2